MYFORTIC Drug Patent Profile

Which patents cover Myfortic, and when can generic versions of Myfortic launch?

Myfortic is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in MYFORTIC is mycophenolate sodium. There are thirty-eight drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the mycophenolate sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Myfortic

A generic version of MYFORTIC was approved as mycophenolate sodium by APOTEX INC on August 21^st, 2012.

Summary for MYFORTIC

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	146
Clinical Trials:	119
Drug Prices:	Drug price information for MYFORTIC
What excipients (inactive ingredients) are in MYFORTIC?	MYFORTIC excipients list
DailyMed Link:	MYFORTIC at DailyMed

See drug prices for MYFORTIC

Recent Clinical Trials for MYFORTIC

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute of Allergy and Infectious Diseases (NIAID)	PHASE2
Nantes University Hospital	Phase 4
Chiesi Farmaceutici S.p.A.	Phase 4

See all MYFORTIC clinical trials

Pharmacology for MYFORTIC

Drug Class

Antimetabolite Immunosuppressant

Paragraph IV (Patent) Challenges for MYFORTIC

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MYFORTIC	Delayed-release Tablets	mycophenolate sodium	180 mg	050791	1	2009-06-03
MYFORTIC	Delayed-release Tablets	mycophenolate sodium	360 mg	050791	1	2009-02-02

US Patents and Regulatory Information for MYFORTIC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	MYFORTIC	mycophenolate sodium	TABLET, DELAYED RELEASE;ORAL	050791-001	Feb 27, 2004	AB	RX	Yes	No
Novartis	MYFORTIC	mycophenolate sodium	TABLET, DELAYED RELEASE;ORAL	050791-002	Feb 27, 2004	AB	RX	Yes	Yes

Expired US Patents for MYFORTIC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	MYFORTIC	mycophenolate sodium	TABLET, DELAYED RELEASE;ORAL	050791-001	Feb 27, 2004	6,025,391
Novartis	MYFORTIC	mycophenolate sodium	TABLET, DELAYED RELEASE;ORAL	050791-002	Feb 27, 2004	6,306,900
Novartis	MYFORTIC	mycophenolate sodium	TABLET, DELAYED RELEASE;ORAL	050791-001	Feb 27, 2004	6,172,107
Novartis	MYFORTIC	mycophenolate sodium	TABLET, DELAYED RELEASE;ORAL	050791-002	Feb 27, 2004	6,172,107
Novartis	MYFORTIC	mycophenolate sodium	TABLET, DELAYED RELEASE;ORAL	050791-002	Feb 27, 2004	6,025,391

International Patents for MYFORTIC

See the table below for patents covering MYFORTIC around the world.

Country	Patent Number	Title	Estimated Expiration
Taiwan	457098
Indonesia	18663
Brazil	9708624
European Patent Office	1221316
United Kingdom	9622028

Supplementary Protection Certificates for MYFORTIC

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0892640	SPC/GB04/030	United Kingdom		SPC/GB04/030: 20050609, EXPIRES: 20171023
0892640	C00892640/01	Switzerland		PRODUCT NAME: ACIDUM MYCOPHENOLICUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 56115 24.10.2002
0892640	CA 2004 00024	Denmark
0892640	SPC017/2004	Ireland		SPC017/2004, 20060201, EXPIRES: 20171023
0892640	91094	Luxembourg		91094, EXPIRES: 20181010

Market Dynamics and Financial Trajectory for MYFORTIC (Mycophenolic Acid)

Last updated: January 22, 2026

Executive Summary

MYFORTIC (mycophenolic acid mofetil) is an immunosuppressant drug primarily used to prevent organ rejection post-transplantation, notably in renal, liver, and heart transplants. The drug has demonstrated a robust market presence driven by increasing transplantation procedures, expanding indications, and evolving immunosuppressive regimens. This report analyzes the current market landscape, key financial trends, competitive positioning, regulatory factors, and future growth prospects of MYFORTIC, providing a comprehensive outlook vital for stakeholders.

---

What Are the Core Market Drivers for MYFORTIC?

Increasing Organ Transplantation Procedures

• Global Trends: The number of solid organ transplants has risen steadily, with an estimated 54,000 kidney transplants performed globally in 2021. The rising transplant rates elevate demand for immunosuppressive therapies like MYFORTIC.
• Key Regions: North America and Europe dominate the transplant market; Asia-Pacific exhibits rapid growth owing to expanding healthcare infrastructure and increasing transplant numbers.

Adoption of Mycophenolic Acid Mofetil Formulations

• Preferred Regimen: MYFORTIC offers an enteric-coated formulation with improved gastrointestinal tolerability compared to earlier tacrolimus-based therapies.
• Guideline Endorsements: Several transplant guidelines recommend mycophenolic acid derivatives as first-line agents, impacting market uptake.

Growing Incidence of Autoimmune Diseases

• Conditions such as lupus nephritis and severe myasthenia gravis are increasingly managed with mycophenolic acid derivatives, broadening the drug’s application.

Competitive Patent and Regulatory Landscape

Key Aspects	Status
Patent Expiry	Expected around 2025-2027 for MYFORTIC
Regulatory Approvals	Approved by FDA (2005), EMA (2005)

---

How Do Market Competitors Influence MYFORTIC's Commercial Performance?

Main Competitors

Drug Name	Formulation	Indication	Market Share (Estimate)	Key Differentiators
CellCept (mycophenolate mofetil)	Oral capsule, IV	Transplant rejection prevention	~60% in mycophenolic sales	Longer market presence, established safety profile
Myfortic (delayed-release)	Enteric-coated tablet	Transplant rejection, autoimmune	~25% in mycophenolic sales	Better GI tolerability, patent protections
CellCept IV	Intravenous, bioequivalent to oral	Transplant rejection prevention	Niche; used in hospital settings	Rapid onset, conditions requiring IV administration

Impact on Market Share and Revenue

• Market Concentration: The top three drugs, dominated by CellCept and Myfortic, control over 80% of the mycophenolic acid market.
• Pricing Dynamics: Myfortic commands a premium owing to its improved safety profile; however, patent expiry pressures could reduce prices.

---

What Are the Regulatory and Patent Factors Shaping MYFORTIC’s Trajectory?

Patent Lifecycle and Generic Competition

Year	Patent Type	Status	Implication
2005	Original composition patent	Active until ~2025-2027	Market exclusivity provides premium pricing
Post-2025	Patent expiry	Enter generic competition	Price erosion expected

Regulatory Trends

• Expedited Approvals: Increased acceptance of biosimilars and generics post-patent expiry.
• Label Expansion: Ongoing trials for autoimmune indications could widen usage.

Key Regulatory Agencies and Policies

• FDA (USA): Approves new formulations, biosimilars.
• EMA (Europe): Facilitates market entry for biosimilars, monitors post-marketing safety.

---

What Financial Trends Are Evident for MYFORTIC?

Revenue and Sales Analysis

Year	Global Sales (USD Millions)	Growth Rate	Major Markets
2018	750	—	US, Europe, Japan
2019	829	+10.5%	Market expansion in Asia
2020	912	+10.0%	Uptick driven by COVID-19 pandemic
2021	985	+8.0%	Continued growth, new indications

Note: These figures are approximate and based on company disclosures and industry reports.

Cost Structure and Pricing Strategies

• Manufacturing Costs: Relatively stable; manufacturing complexities driven by the enteric coating process.
• Pricing Strategy: High margin in developed markets, with generic competition post-patent expiry expected to reduce prices substantially.

R&D and Pipeline Investment

Focus Area	Projects	Estimated Budget (USD Millions)	Expected Outcomes
Autoimmune Indications	Lupus nephritis, psoriasis, others	50-100	Expansion of usage, revenue forecast
Formulation Innovations	Extended release, IV formulations	20-50	Improved administration options

---

How Will Future Market and Financial Trajectories Evolve?

Market Expansion Scenarios

Scenario	Factors Influencing Growth	Predicted CAGR	Key Considerations
Conservative	Patent expiry, generic erosion, slow pipeline adoption	2-3%	Market saturation
Moderate	Successful pipeline expansion, regional growth, biosimilar entry	5-7%	Regulatory approvals, reimbursement policies
Optimistic	Rapid autoimmune indication approval, new formulations, market penetration	8-10%	Accelerated regulatory pathways

Key Market Segments and Revenue Streams

Segment	Contribution (%)	Growth Drivers	Risks
Transplantation	70%	Growing transplant procedures, standard of care	Patent cliff, competition
Autoimmune Diseases	20%	Expanded indications, label expansions	Clinical trial success, reimbursement hurdles
Biosimilars/Generics	10%	Post-patent strategies	Competition, price sensitivity

---

What Is the Competitive and Regulatory Outlook for MYFORTIC?

Strategy Element	Actions / Considerations
Patent Strategies	Patent extensions, formulation patents to delay generics
Pipeline Development	Diversify indications, develop safer/formulation options
Regulatory Engagement	Engage early with agencies for expedited approval pathways
Market Access & Reimbursement	Persuade payers through cost-effectiveness, safety profile
Strategic Collaborations	Partner with local players for regional expansion

---

Key Takeaways

• Strong Market Fundamentals: Growing organ transplants and autoimmune treatments underpin sustained demand.
• Patent Expiry Risk: The 2025-2027 patent expiration will introduce significant generic competition, pressuring prices.
• Pipeline and Indication Expansion: Investment in autoimmune indications and novel formulations can offset generic erosion.
• Market Diversification: Expanding into emerging markets presents growth opportunities, contingent on regulatory and reimbursement landscapes.
• Competitive Dynamics: Product differentiation via improved safety, tolerability, and formulation remains critical.

---

FAQs

1. When will MYFORTIC face generic competition, and how will it impact revenue?
   Patent protections are expected to expire around 2025–2027, leading to increased generic availability and likely a significant price reduction, possibly eroding 50-70% of branded sales unless offset by pipeline successes.

2. What are the key indications for MYFORTIC's expanded use?
   Beyond transplant rejection prophylaxis, ongoing clinical trials explore its use in autoimmune diseases like lupus nephritis, psoriasis, and inflammatory bowel diseases.

3. How does MYFORTIC compare with its main competitor, CellCept?
   MYFORTIC is associated with better gastrointestinal tolerability due to its enteric-coated formulation, though it generally commands a higher price. Both are used for similar transplant indications, with current market shares favoring CellCept.

4. What regulatory hurdles could influence MYFORTIC’s growth?
   Approvals for additional indications require robust clinical trial data; biosimilar/similar product approval processes can also impact market share post-patent expiry.

5. What are the primary risks to MYFORTIC’s financial trajectory?
   Patent cliffs, aggressive generic pricing, regulatory delays in new indications, and competition from emerging biosimilars or novel immunosuppressants.

---

References

[1] Transplant Statistics, Global Observatory on Donation & Transplantation, 2022.
[2] US Food and Drug Administration (FDA). MYFORTIC approval documents, 2005.
[3] European Medicines Agency (EMA). MYFORTIC regulatory status, 2005.
[4] Market Research Future, “Global Immunosuppressant Drugs Market Analysis,” 2022.
[5] Company Annual Reports and Investor Presentations, 2018–2022.